CK Biotech Inc

[Not Yet Scheduled]
We develop First-in-Class drugs targeting CXXC5, a negative feedback regulator of the Wnt/Beta-catenin pathway, which is overexpressed in tissues of bald, wounded, obese diabetes and NASH patients. CXXC5 as a target for development of drugs for treatment of these diseases is confirmed by phenotypes for CXXC5 knock out mice and by developing the PTD-DBM peptide interfering CXXC5 binding to Dvl. By topical application, the peptide induced neogenic hair growth and wound healing via activating Wnt signaling. With the development of PTD-DBM as a new concept therapeutics for hairloss and wound, we further screened and characterized small molecules inhibiting CXXC5-Dvl protein-protein interaction (PPI). 90 analogs for one of hits were newly synthesized, and several candidates are on the way of pre-clinical stage for treatment of obesity, diabetes, NASH, hair loss and wound healing. The candidates are specific to the patients who overexpressed CXXC5 without any noticeable abnormalities.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
NCE
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
7
Speaker
photo
CEO
CK Biotech Inc